Cargando…

Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab

Single-agent immune checkpoint inhibitor therapy in advanced non-small cell lung cancer can significantly prolong progression-free and overall survival when compared with cytotoxic chemotherapy. Here, we report a case of newly diagnosed adenocarcinoma of the lung with a solitary brain metastasis and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saltman, David L., Nielsen, Tyler J., Salina, Davide, Hout, David R., McMahon, Frank B., Valev, Boris R., Huk, Michael, Chandra, Pranil K., Spille, Jeremy, Seitz, Robert S., Schweitzer, Brock L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058789/ https://www.ncbi.nlm.nih.gov/pubmed/33953802 http://dx.doi.org/10.1177/17588359211010156

Ejemplares similares

A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies
por: Nielsen, Tyler J., et al.
Publicado: (2021)

Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
por: Hout, David R., et al.
Publicado: (2017)

A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer
por: Iwase, Toshiaki, et al.
Publicado: (2021)

Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research
por: Espinosa Fernandez, Jose Rodrigo, et al.
Publicado: (2020)

Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer
por: Ranganath, Harsha, et al.
Publicado: (2022)

Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients
por: Ring, Brian Z., et al.
Publicado: (2016)

Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients
por: Ring, Brian Z., et al.
Publicado: (2016)

Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease
por: Lawrence, Kasey, et al.
Publicado: (2015)

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort
por: Nielsen, Tyler J., et al.
Publicado: (2023)

Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue
por: Jovanović, Bojana, et al.
Publicado: (2017)

Successful treatment of hepatic oligometastases with stereotactic ablative radiotherapy and radiofrequency ablation in an anaplastic lymphoma kinase fusion‐positive lung cancer patient
por: Weber, Britta, et al.
Publicado: (2015)

Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination
por: van der Woude, Lieke L, et al.
Publicado: (2022)

Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings
por: Dobriyan, Alex, et al.
Publicado: (2021)

Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
por: Glencer, Alexa C., et al.
Publicado: (2021)

Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma
por: Kichloo, Asim, et al.
Publicado: (2020)

Pembrolizumab
por: Khoja, Leila, et al.
Publicado: (2015)

Retraction: Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings
Publicado: (2022)

Genetic landscape of prognostic value in pancreas ductal adenocarcinoma microenvironment—reply
por: Pu, Ning, et al.
Publicado: (2020)

Characterization and digital spatial deconvolution of the immune microenvironment of intraductal oncocytic papillary neoplasms (IOPN) of the pancreas
por: Pea, Antonio, et al.
Publicado: (2023)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

Pembrolizumab for all
por: Kim, Myung S., et al.
Publicado: (2022)

Targeting focal adhesion kinase reprograms the pancreatic tumor microenvironment and renders pancreas cancer responsive to checkpoint immunotherapy
por: Jiang, Hong, et al.
Publicado: (2015)

Pancreas-kidney transplantation is associated with reduced fracture risk compared to kidney alone transplantation in men with type 1 diabetes
por: Nikkel, Lucas E., et al.
Publicado: (2013)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
por: Larsen, Frederik Uttenthal, et al.
Publicado: (2019)

Incremental Value of the Pancreas Allograft to the Survival of Simultaneous Pancreas-Kidney Transplant Recipients
por: Salvalaggio, Paolo R., et al.
Publicado: (2009)

Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients
por: Seitz, Robert S., et al.
Publicado: (2022)

Pembrolizumab-Induced Toxic Epidermal Necrolysis
por: Borg, Luca, et al.
Publicado: (2022)

Renal toxicities associated with pembrolizumab
por: Izzedine, Hassan, et al.
Publicado: (2018)

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy
por: Murakami, Shuji, et al.
Publicado: (2020)

A Rare Case of Pembrolizumab-Induced Reactivation of Hepatitis B
por: Pandey, Anita, et al.
Publicado: (2018)

Staging cancer of the pancreas
por: Morana, G., et al.
Publicado: (2010)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Pembrolizumab-associated sarcoidosis
por: Cotliar, Jonathan, et al.
Publicado: (2016)

Pembrolizumab-induced pneumonitis
por: Leroy, Vincent, et al.
Publicado: (2017)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
por: Mimura, Kaito, et al.
Publicado: (2022)

Immunogenicity of pembrolizumab in patients with advanced tumors
por: van Vugt, Marianne J. H., et al.
Publicado: (2019)

Artificial Pancreas: Past, Present, Future
por: Cobelli, Claudio, et al.
Publicado: (2011)

Pembrolizumab-induced rash in a patient with angiosarcoma
por: Qian, Justin, et al.
Publicado: (2022)

Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab
por: Alnajar, Hussein, et al.
Publicado: (2022)

Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
por: Shoushtari, Alexander N., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_liemqsk182sa7tdt73l571j01m